Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Alexion Pharmaceuticals, Inc. (ALXN)

182.5   0 (0%) 10-01 10:15
Open: 181.04 Pre. Close: 182.5
High: 182.67 Low: 180.21
Volume: 3 Market Cap: 40,336(M)
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 211.18 - 212.67 212.67 - 213.83
Low: 205.68 - 207.27 207.27 - 208.51
Close: 206.91 - 209.34 209.34 - 211.23

Technical analysis

as of: 2022-09-30 4:26:06 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 272.18     One year: 292.43
Support: Support1: 205    Support2: 170.55
Resistance: Resistance1: 233.03    Resistance2: 250.36
Pivot: 221.39
Moving Average: MA(5): 209.48     MA(20): 223.23
MA(100): 234.39     MA(250): 250.31
MACD: MACD(12,26): -8.2     Signal(9): -6.7
Stochastic oscillator: %K(14,3): 13.3     %D(3): 10.6
RSI: RSI(14): 30.4
52-week: High: 299.98  Low: 205
Average Vol(K): 3-Month: 9 (K)  10-Days: 10 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ALX ] has closed above bottom band by 18.1%. Bollinger Bands are 50.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Headline News

Thu, 29 Sep 2022
US close: Stocks weaker on hawkish Fed commentary | Financial News - London South East

Wed, 28 Sep 2022
Apellis Pharmaceuticals Stock: Trying To Develop A Blockbuster Franchise (NASDAQ:APLS) - Seeking Alpha

Thu, 23 Jun 2022
ALXN1840 shows rapid and sustained improvement in copper mobilisation from tissues, potentially closing treatment gaps for Wilson disease community - AstraZeneca

Wed, 21 Jul 2021
AstraZeneca closes mega $39B Alexion buyout despite antitrust fears, making a splash in rare diseases - FiercePharma

Wed, 21 Jul 2021
Acquisition of Alexion completed - AstraZeneca

Thu, 15 Jul 2021
Why Alexion Pharmaceuticals (ALXN) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 5 (M)
Shares Float 2 (M)
% Held by Insiders 58.7 (%)
% Held by Institutions 39.9 (%)
Shares Short 138 (K)
Shares Short P.Month 139 (K)

Stock Financials

EPS 22.65
EPS Est Next Qtl 0
EPS Est This Year 23.22
EPS Est Next Year 23.62
Book Value (p.s.) 48.93
Profit Margin (%) 59.9
Operating Margin (%) 37.3
Return on Assets (ttm) 3.2
Return on Equity (ttm) 50.9
Qtrly Rev. Growth -3
Gross Profit (p.s.) 22.51
Sales Per Share 38.67
EBITDA (p.s.) 20.53
Qtrly Earnings Growth -42.8
Operating Cash Flow 149 (M)
Levered Free Cash Flow 86 (M)

Stock Valuations

PE Ratio 9.22
PEG Ratio 0
Price to Book value 4.27
Price to Sales 5.4
Price to Cash Flow 7.15

Stock Dividends

Dividend 4.5
Forward Dividend 0
Dividend Yield 2.1%
Dividend Pay Date 2021-11-18
Ex-Dividend Date 2021-11-04
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.